Filter
1462
Filtered Results: 1462
Text search:
treatment
interruption
Featured
Recommendations
166
New Publications
389
Language
Document type
No document type
843
Studies & Reports
240
Guidelines
199
Manuals
63
Strategic & Response Plan
63
Training Material
26
Fact sheets
13
Situation Updates
11
Brochures
2
Resource Platforms
1
Infographics
1
Countries / Regions
India
74
Global
50
Kenya
33
Western and Central Europe
33
Ethiopia
32
Malawi
31
Liberia
31
Sierra Leone
28
Latin America and the Carribbean
27
Nepal
23
Tanzania
20
Zambia
20
Nigeria
19
Bangladesh
19
South Africa
19
Africa
17
Ghana
16
Ukraine
15
Namibia
14
Syria
13
Guinea
13
Congo, Democratic Republic of
13
Eastern Europe
13
Myanmar / Burma
13
Rwanda
12
Philippines
12
Haiti
12
Uganda
12
Venezuela
11
South Sudan
11
Lesotho
10
Paraguay
10
Pakistan
9
Colombia
8
Senegal
8
Zimbabwe
8
Cambodia
8
West and Central Africa
7
Ecuador
7
Afghanistan
6
Peru
6
Mozambique
6
South–East Asia Region
6
East and Southern Africa
6
Cameroon
5
Albania
5
Germany
5
Bolivia
5
Yemen
5
Central African Republic
5
Botswana
5
Jordan
4
Western Pacific Region
4
Argentina
4
Sri Lanka
4
Russia
4
Georgia
4
Burkina Faso
3
Middle East and North Africa
3
Eastern Europe and Central Asia
3
Brazil
3
Palestine
3
Libya
3
Timor Leste/ East Timor
2
Thailand
2
Benin
2
Chile
2
Iran
2
Canada
2
USA
2
North America
2
Lebanon
2
Sudan
2
Honduras
2
Angola
2
Indonesia
2
Madagascar
2
Eswatini/ Swaziland
2
El Salvador
1
Turkey
1
Gambia
1
China
1
Kazakhstan
1
Fiji
1
Singapore
1
Estonia
1
Kyrgyzstan
1
Qatar
1
Bulgaria
1
Italy
1
Asia
1
Hungary
1
Saudi Arabia
1
Turkmenistan
1
Mauritius
1
Spain
1
Côte d’Ivoire / Ivory Coast
1
Vietnam
1
Moldova
1
Djibouti
1
Egypt
1
Romania
1
Greece
1
Poland
1
Mali
1
Chad
1
Iraq
1
Somalia
1
Guatemala
1
Authors & Publishers
Publication Years
Category
Countries
510
Clinical Guidelines
147
Public Health
70
Women & Child Health
67
Key Resources
62
Capacity Building
33
Pharmacy & Technologies
13
Toolboxes
TB
193
HIV
169
COVID-19
124
Mental Health
93
NTDs
84
Conflict
49
Refugee
34
Ebola
34
Rapid Response
33
Caregiver
29
Planetary Health
26
Natural Hazards
23
Disability
19
Pharmacy
17
Polio
15
AMR
15
Cholera
13
NCDs
12
Global Health Education
10
Health Financing Toolbox
6
Zika
6
Specific Hazards
5
Social Ethics
2
Typhoon
2
South Sudan
1
Chagas disease (American trypanosomiasis) is endemic in 21 countries of the Americas, where control is largely focused on elimination of the domestic insect vectors (Triatominae) coupled with measures to extend and improve the screening of blood donors in order to avoid tranfusional transmission. Th...
Chagas disease (CD) is endemic in the Americas, being present in 21 countries, where it affects about 6 million
people.(1) With such relevant numbers of people affected and disability adjusted life years lost, CD is a poverty-related
and poverty-promoting disease.
Although data describe a relevan...
Sleeping sickness is controlled by case detection and treatment but this often only reaches less than 75% of the population. Vector control is capable of completely interrupting HAT transmission but is not used because of expense. We conducted a full scale field trial of a refined vector control tec...
Following the publication of Guidelines on certification of elimination of human onchocerciasis in 2001 by the World Health Organization (WHO), these are the first evidence-based guidelines developed by NTD Department according to the international standards. They provide a set of recommendations th...
Gambiense human African trypanosomiasis is a deadly infectious disease affecting West and Central Africa, South Sudan and Uganda, and transmitted between humans by tsetse flies. The disease has caused several major epidemics, the latest one in the 1990s. Thanks to recent innovations such as rapid di...
Результаты исследования «Изучение распространенности коронавирусной инфекции COVID-19 среди инфицированных ВИЧ пациентов вРоссии ивлияния эпидемии коронавирусной...
It estimates that there have been 228,000 additional deaths of children under five in these six countries [Afghanistan, Nepal, Bangladesh, India, Pakistan and Sri Lanka] due to crucial services, ranging from nutrition benefits to immunisation, being halted.
It says the number of children being tr...
the Lancet Infectious Diseases Published online March 22, 2022 https://daoi.org/10.1016/S1473-3099(22)00214-6
Summary of the main report: Direct and indirect effects of COVID-19 pandemic and response in South Asia .
It uses a series of exercises based on actual observed changes in services and intervention coverage to model impacts on mortality, hospitalizations, and ICU admissions due to COVID-19. It a...
Guidelines for treatment of drug-susceptible tuberculosis and patient care
2017 update
Guidelines for treatment of drug-susceptible tuberculosis and patient care
Update 2017
Guidelines for treatment of drug-susceptible tuberculosisand patient care
2017 Update
4th edition. This is fourth edition of Treatment of tuberculosis: guidelines, adhering fully to the new WHO process for evidence-based guidelines. Several important recommendations are being promoted in this new edition
We systematically reviewed Medline as well as the references of published review articles for relevant studies of adherence to multidrug treatment of both drug-susceptible and drug-resistant TB through February 3, 2018. We included randomized controlled trials (RCTs) as well as prospective and retro...
The guidelines are aimed at clinical professionals directly involved with and responsible for the care of adults with HIV infection, and at community advocates responsible for promoting the best interests and care of HIV-positive adults. They should be read in conjunction with other published BHIVA ...
This document provides technical guidance on concepts, definitions, indicators, criteria, milestones and tools to assist leprosy programmes in their journey towards the goals of interruption of transmission and elimination of leprosy disease and through the post-elimination period. Importantly, it p...
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.
